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Abstract
Background: Studies have found that antipsychotics and antidepressants are associated with weight gain and
obesity, particularly among women and some minority groups. Incarcerated populations (also referred to as
offenders, prisoners or inmates) have a high prevalence of mental health problems and 15 % of offenders have
been prescribed medications. Despite rates of antidepressant and antipsychotic use, investigations of weight gain
and obesity in regard to these agents seldom have included offenders.
Methods: This retrospective descriptive study (2005–2011) was conducted with a Department of Corrections in the
east south central United States to investigate the relationship between antidepressant and antipsychotic agents,
weight gain, obesity and race or gender differences. We sampled adult offenders who had an active record, at least
two weight observations and height data. Offenders were classified into one of four mutually exclusive groups
depending upon the type of medication they were prescribed: antidepressants, antipsychotics, other medications or
no pharmacotherapy.
Results: The sample population for this study was 2728, which was 25.2 % of the total population. The population
not on pharmacotherapy had the lowest baseline obesity rate (31.7 %) compared to offenders prescribed
antipsychotics (43.6 %), antidepressants (43.6 %) or other medications (45.1 %). Offenders who were prescribed
antidepressants or antipsychotics gained weight that was significantly different from zero, p < .001 and p = .019,
respectively. Women in the antidepressant group gained 6.4 kg compared to 2.0 kg for men, which was significant
(p = .007). Although women in the antipsychotic group gained 8.8 kg compared to 1.6 kg for men, the finding was
not significant (p = .122). Surprisingly, there were no significant differences in weight gain between African
Americans and Whites in regard to antidepressants (p = .336) or antipsychotic agents (p = .335).
Conclusion: This study found that women and men offenders prescribed antidepressant or antipsychotic agents
gained weight during their incarceration. Women prescribed antidepressants gained significantly more weight than
men. However, there was no significant difference in weight gain between African Americans and Whites. Results
suggest further investigation is needed to understand the effect of medication history, metabolic syndrome and to
explain gender disparities.
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Background
Obesity risk factors are complex and multifaceted, com-
prised of behaviors related to physical inactivity and ex-
cess caloric intake, as well as the environment where
people live and social conditions, such as education and
poverty (CDC 2015). Along with behavioral, environ-
mental and social factors, studies have found that anti-
psychotic agents are associated with weight gain and
obesity, which is known to increase risk for diabetes,
cardiovascular and other chronic diseases (Bai et al.
2015; Ghanizadeh et al. 2013; Henderson et al. 2015;
Jafari et al. 2012; Zuo et al. 2015). Antipsychotics also
have been linked to the expression of genes related to
obesity (Fonseka et al. 2015; Shams & Muller 2014; Tek
et al. 2013; Tiwari et al. 2015). Obesity and weight gain
also have been associated with the use of antidepressants
(Grundy et al. 2014; Heiskanen et al. 2013).
The prevalence of obesity and weight gain are not dis-
tributed proportionately across populations, especially in
regard to gender and race (Papanastasiou 2013). Antide-
pressants studies, particularly ones investigating sero-
tonin re-uptake inhibitors, found that women who were
prescribed these agents gained more weight and were
more likely to be obese or to experience metabolic dys-
regulation compared to men (Bet et al. 2013; Grundy
et al. 2014; Keers & Aitchison 2010; Noordam et al.
2015). Further, women who were prescribed antipsy-
chotics experienced greater weight gain and had more
significant metabolic abnormalities than men (Seeman
2010; Softic et al. 2015; Wysokinski et al. 2012). In re-
gard to race, African American patients diagnosed with
schizophrenia and prescribed antipsychotic agents
gained significantly greater weight compared to White
peers (Chan et al. 2013; Krakowski et al. 2009; Stauffer
et al. 2010). Contrarily, a few studies have not found a
relationship between weight gain and gender or race
(Fava et al. 2009). However, studies that have found gen-
der and race disparities related to antidepressant and
antipsychotic agents have not been definitive in regard
to the mechanisms (genetic expressions and environ-
ment) and their relative effects mediating weight gain
and obesity (Chan et al. 2013; Keers & Aitchison 2010;
Seeman 2010).
Offenders (also referred to as prisoners or inmates in
some jurisdictions and countries) also are at risk for dis-
proportionate rates of obesity (Maruschak et al. 2015),
along with high prevalence of mental health problems
that are treated by medications (Glaze & James 2006).
Studies have found that adult offenders, a vulnerable
and priority population for poor health, gain weight and
become obese during their incarceration, contributing to
their increased risk for related conditions, such as dia-
betes and cardiovascular diseases (Bai et al. 2015; Clarke
& Waring 2012; Herbert et al. 2012; Wolff et al. 2012).
Incarcerated populations also have higher prevalence
of mental health problems than the general population
(Glaze & James 2006; Hassan et al. 2014; Visher & Bak-
ken 2014). The United States Bureau of Justice Statistics’
assessment of mental health in corrections (i.e., prisons)
found that 24 % of all offenders incarcerated in state
prisons (i.e., lengths of incarceration typically exceeding
one year and involving more serious offenses) reported
that they had a recent history of a mental health prob-
lem (Glaze & James 2006). Large percentages of of-
fenders in state correctional facilities reported having
depression (23.5 %) and psychotic symptoms (15.4 %)
(Glaze & James 2006). Among offenders in state prisons
who had mental health problems, 15 % were prescribed
medication (Glaze & James 2006).
The association between weight gain and obesity with
antipsychotics and antidepressants primarily has been
investigated in non-incarcerated populations, despite the
rates in which these medications have been prescribed
in corrections. Studies that have included non-
incarcerated populations have investigated antipsychotic
induced weight gain (AIWG) (Bak et al. 2014; Curtis
et al. 2015; Henderson et al. 2015; Shams & Muller
2014; Tek et al. 2013; Tek et al. 2015; Wang et al. 2014),
interventions to minimize weight gain for patients taking
these agents (Curtis et al. 2015; Ghanizadeh et al. 2013;
Jacobowitz et al. 2014; Mahmood et al. 2013; Mizuno
et al. 2014; Wu et al. 2012; Zheng et al. 2015) and health
disparities in regard to gender, race and ethnicity (Berkowitz
& Fabricatore 2011; Chan et al. 2013; Hassan et al. 2014).
These studies found a strong relationship between weight
gain and use of antipsychotics (Bak et al. 2014; Curtis et al.
2015; Henderson et al. 2015; Shams & Muller 2014;
Tek et al. 2013; Tek et al. 2015; Wang et al. 2014) and
antidepressants (Berkowitz & Fabricatore 2011; Grundy
et al. 2014).
This descriptive study investigated offenders in a state
department of corrections to explain the relationship
among changes in weight, psychotropic agents (i.e., anti-
depressants and antipsychotics) and incarceration. The
primary goal of this study was to investigate the effect
that some psychotropic agents have on changes in
weight. We hypothesized the following:
1. Patients who have ever been prescribed either
antidepressants or antipsychotics (first or second
generation) gain more weight during their
incarceration compared to the population that has
no history of being prescribed these type of agents
(i.e., offenders who are prescribed other medications
or no pharmacotherapy).
2. There are gender and race differences in regard to
weight gain for patients who have ever been
prescribed either antidepressants or antipsychotics.
Gates et al. Health and Justice  (2016) 4:6 Page 2 of 12
a. Women who have ever been prescribed
antidepressants or antipsychotics gain more
weight than men.
b. African Americans who have ever been
prescribed antidepressants or antipsychotics gain
more weight than Whites.
Methods
This retrospective descriptive study was approved by an
institutional review board (IRB), Protocol number: 10-
0382F2L, at an academic health center and was conducted
for 2005–2011 in collaboration with a Department of
Corrections (DOC) in the east south central region of the
United States.
The DOC for this study had an electronic health record
(EHR), from which all health data (diagnoses, medication
classification, height and weight values) were extracted.
Clinic staff created an electronic record for all offenders
upon their arrival at the DOC reception center, an assess-
ment facility where everyone received a complete physical,
mental health and dental examination. The DOC also
used an offender management system (OMS), an elec-
tronic tracking and case management system, which col-
lected demographic, social, criminal record (offense),
sentence and parole data. The offender management rec-
ord was created electronically and managed by correc-
tional officers and case managers.
Inclusion and exclusion criteria
The data extraction criterion for the EHR and OMS was
active records (i.e., offenders currently incarcerated) be-
tween June 1, 2005 and December 31, 2010. The date
range was determined by the implementation of the
DOC’s EHR, which occurred in 2005. All adult offenders
(men and women) were eligible for inclusion. Offenders
were excluded if they did not have at least two weight
observations, a baseline and post baseline value (last re-
corded weight), and if they did not belong to a mutually
exclusive medication group. Offenders also were ex-
cluded if there were no valid height data and their length
of incarceration was not greater than zero. Offenders
who met the inclusion criteria were assigned to a medi-
cation group based on pharmacy data identifying
whether or not an offender had been prescribed an anti-
depressant or antipsychotic. These data allowed us to cre-
ate four mutually exclusive groups: antidepressants,
antipsychotics, other medications or no pharmacotherapy.
Data collection
Health record data for this study were primarily struc-
tured (i.e., users selected or entered data into the record,
using standardized data dictionaries). Prescriptions were
generated electronically using the National Drug Code
(NDC). Diagnoses were entered using International
Statistical Classification of Diseases (ICD-9) and supple-
mented by the Systematized Nomenclature of Medicine
(SNOMED). The structured nature of prescriptions
and diagnoses provided a degree of standardization.
Clinic staff, primarily nurses, entered height and
weight data. Data from the OMS were primarily en-
tered by correctional officers into discreet fields. Race,
ethnicity and gender were pre-populated based on
court records.
Anthropometric data, such as body mass index (BMI),
were not available in the extracted data; BMI was calcu-
lated as weight in kilograms (kg) divided by height in
meters squared (BMI = weight in kg/height in m2). The
calculated BMIs were classified using the World Health
Organization’s (WHO) cut-off points (WHO 2004), as
shown in Table 1. Percent weight change [(last weight –
baseline-weight)/baseline weight] was calculated and used
to determine whether or not offenders gained medically sig-
nificant weight (weight gain ≥ 7 % of baseline weight)
(Arterburn et al. 2015; Bak et al. 2014; Curtis et al. 2015;
Lencz & Malhotra 2009; Maayan & Correll 2010; Stauffer
et al. 2010; Tek et al. 2015).
Statistical analyses
SAS® 9.4 (SAS Institute, Cary, NC) was used to conduct
statistical tests. Frequencies and percentages were con-
ducted for nominal and categorical variables, such as
race, gender, BMI classification, and medications. Means
and standard deviations (SD) were calculated for con-
tinuous variables, including BMI, and percent weight
change, length of time between weight observations.
Chi-square (χ2) was computed to evaluate whether or
not populations have different proportions and odds ra-
tios were computed to determine if the four mutually
exclusive medication groups (antidepressant, anti-
psychotic, other medication and no pharmacotherapy)
differed in regard to exposure (medication use) and re-
sponse (changes in weight). Differences in baseline and
last weight observation (end of study) were examined
using paired t-test to determine if the different groups
on average gained weight that was statistically significant
from zero. The paired t-test was performed for each
group. Group comparisons for race and gender were





Obesity Class I 30.0–34.9
Obesity Class II 35.0–39.9
Obesity Class III ≥40.0
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made using the Wilcoxon rank-sum test. Comparisons
for race were limited to African Americans and Whites,
since there were too few other race and ethnic popula-
tions for meaningful analyses. The Kruskal-Wallis test
was computed to evaluate differences among the four
medication groups. To adjust for multiple comparisons
and the increased probability of a Type I error (a false
positive), we performed the Bonferroni correction, which
evaluates the significance of pairwise comparisons using
an adjusted alpha (α/n, where n = number of pairwise
comparisons).
Results
This study sampled 2728 offenders (25.2 %) out of a
population of 10,841 who met the inclusion criteria (e.g.,
valid weight and height observations). A large percent of
the population was excluded for the following reasons:
1) medication groups were mutually exclusive; 2) of-
fenders without chronic diseases did not report to clinics
regularly and did not always have multiple weight obser-
vations; 3) patients primarily seen for mental health is-
sues did not have vital statistics recorded in the health
record on a consistent basis; 4) a segment of the popula-
tion had not been incarcerated long enough to have
multiple weight values.
Despite excluding a large percent of the population,
African Americans and offenders prescribed antidepres-
sants or antipsychotics were overrepresented in the
study sample; however, the percent of women offenders
was less than the total population (Table 2). Although
the study sample and total population differed
statistically (e.g., race and gender), both groups were ma-
jority White, male, not prescribed any medication and
had a primary offense related to violence (Table 2). The
mean age was 40.2 for the study sample and 37.5 for the
total population (Table 2).
Table 3 shows that medication groups had similar
BMIs at baseline and last observation; however, the no
pharmacotherapy group had the lowest BMI (28.0) com-
pared to a BMI ≥ 30 for the other groups. A comparison
of the three medication groups (antidepressants, antipsy-
chotics and other medications) indicated that baseline
BMI was not significantly different (p = .353). The three
groups also did not have significantly different last ob-
served BMI (p = .913). Further, when antipsychotics (first
generation and second generation) were compared, their
baseline BMI was not significantly different (p = .860); last
observed BMI also was not significantly different (p = .795)
between the two subgroups. Table 3 also shows that the
average length of time between baseline and last observed
BMI for the three groups prescribed a medication ranged
from 2.3 to 2.5 years, which was not significantly different
(p = .204). When the length of time between baseline and
last observed BMI for first generation antipsychotics (FGA)
and second generation antipsychotics (SGA) were com-
pared (Table 3), the two subgroups also were not signifi-
cantly different (p = .143).
There were few offenders entering corrections who
had a BMI classified as normal or underweight, as
shown in Table 4. A plurality of offenders across medica-
tion groups (antidepressant, antipsychotic and other
medications) entered corrections obese. As Table 4
Table 2 Differences between Study and Total Population
Variable Study Total p
n (%) or Mean ± SD n (%) or Mean ± SD
Race
African American 897 (34.2) 3,192 (29.4) < .001
Asian 2 (0.1) 11 (0.1) .423
Hispanic 11 (0.4) 150 (1.4) < .001
American Indian 2 (0.1) 12 (0.1) .625
White 1,657 (63.2) 7,175 (66.2) .004
Unknown 53 (2.0) 297 (2.7) .039
Gender
Men 2,458 (93.8) 9,767 (90.1) < .001
Women 164 (6.3) 1074 (9.9) < .001
Age 40.20 ± 10.3 37.5 ± 11.5 < .001
Violent Offense 864 (48.2) 3,305 (48.4) .901
Medications
Psychotropic 390 (14.9) 1,446 (13.3) .040
Other medications 823 (31.4) 4,487 (41.4) < .001
No pharmacotherapy 1,409 (53.7) 6,136 (56.6) .007
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shows, the population not prescribed pharmacotherapies
entered corrections with the lowest obesity rate (31.7 %)
compared to offenders who used antipsychotics (43.6 %),
antidepressants (43.6 %) or other medications (45.1 %).
Patients on antidepressants had the greatest prevalence
for Obesity Class III at baseline.
As Table 5 shows, the list of prescribed antidepressants
and antipsychotics was not extensive. Amitriptyline was
the most frequently prescribed antidepressant. Risperi-
done and perphenazine were the most often prescribed
SGA and FGA, respectively, while olanzapine was sel-
dom used and no offender in the study used clozapine
(See Table 5). Further, FGA were prescribed more often
than SGA.
The paired t-test was performed for all medications
groups to indicate whether or not offenders in their re-
spective group had changes in weight that was signifi-
cantly different from zero. The test indicated that last
observed weight was greater than baseline for the popu-
lation prescribed antidepressants (p < .001), antipsy-
chotics (p = .019), other medications (p = .018) and the
no pharmacotherapy group (p < .001). In regard to the
antipsychotic subgroups, changes in baseline and last
observed weight was only significant for the population
prescribed SGA (p = .033); FGA had a p-value = .209.
Women and men, who were taking antidepressants,
had weight gain significantly different from zero p < .001
and p = .001, respectively, as did African Americans and
Whites, p = .030 and p < .001, respectively. Although
women and men gained weight while taking antipsy-
chotics, changes between baseline and last weight ob-
served were not significant (p = .066 and p = .093,
respectively). African Americans and Whites, who were
prescribed antipsychotics, also gained weight, but the in-
crease was not significantly different from zero (p = .148
and p = .081, respectively).
The four medication groups also had significantly dif-
ferent proportions (p < .001) in regard to medically sig-
nificant weight gain. Larger proportions of patients
taking antidepressants or antipsychotics (32.7 and
33.1 %, respectively) gained medically significant weight
compared to those on other medications or no pharma-
cotherapy (22.6 % for both groups). There was no sig-
nificant difference in proportions (p = .212) for medically
significant weight gain between patients prescribed FGA
or SGA.
Table 6 shows that offenders prescribed antidepres-
sants gained more weight compared to the antipsychotic,
other medications and no pharmacotherapy groups. Fur-
ther, the Kruskal-Wallis test indicated that weight
Table 3 BMI by Medication Group: Baseline and Last Observation
Baseline BMI Last observation Durationa
95 % CIb 95 % CI 95 % CI
Medication Group Number Mean (SD) [Lower, Upper] Mean (SD) [Lower, Upper] Mean (SD) [Lower, Upper]
Antidepressants 324 30.0 (5.4) [29.4, 30.6] 30.9 (5.4) [30.3, 31.5] 2.3 (1.1) [2.2, 2.4]
Antipsychotics 172 30.0 (6.0) [29.1, 30.9] 30.8 (5.2) [30.0, 31.5] 2.4 (1.1) [2.6, 2.6]
Other medication 823 30.4 (5.6) [30.0, 30.8] 30.7 (5.1) [30.3, 31.0] 2.5 (1.1) [2.4, 2.5]
No pharmacotherapy 1409 28.0 (4.6) [28.6, 29.1] 29.3 (4.4) [29.1, 29.5] 1.9 (1.1) [1.9, 2.0]
Antipsychotics
FGA 99 29.9 (5.7) [28.8, 31.1] 30.5 (4.9) [29.6, 31.5] 2.3 (1.1) [2.1, 2.63]
SGA 73 30.0 (6.3) [28.5, 31.5] 31.0 (5.6) [29.7, 32.4] 2.6 (1.0) [2.4, 2.8]
a Length of time (years) between baseline and last weight observation
b95 % Confidence Interval
Table 4 Distribution of World Health Organization’s BMI Classification on Entry into Corrections
Antidepressants Antipsychotics Other medications No pharmacotherapy
Classification Baseline Last observation Baseline Last observation Baseline Last observation Baseline Last observation
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Underweight 0 (0) 0 (0) 0 (0) 0 (0) 2 (0.2) 1 (0.1) 2 (0.1) 0 (0)
Normal 46 (14.2) 24 (7.4) 32 (18.6) 12 (7) 89 (10.8) 55 (6.7) 247 (17.5) 189 (13.4)
Overweight 137 (42.3) 154 (47.5) 65 (37.8) 84 (48.8) 361 (43.9) 385 (46.8) 712 (50.5) 733 (52)
Obesity I 98 (30.2) 87 (26.9) 49 (28.5) 44 (25.6) 236 (28.7) 254 (30.9) 316 (22.4) 342 (24.3)
Obesity II 21 (6.5) 38 (11.7) 15 (8.7) 21 (12.2) 84 (10.2) 88 (10.7) 99 (7) 104 (7.4)
Obesity III 22 (6.8) 21 (6.5) 11 (6.4) 11 (6.4) 51 (6.2) 40 (4.9) 33 (2.3) 41 (2.9)
324 172 823 1409
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change, percent weight change and change in BMI were
significantly different (p = .027, p = .027 and p = .021 re-
spectively) across the four medication groups. Weight
change, percent weight change and change in BMI are
highly collinear, given that all the variables are derived
from weight observations and evidenced by the similar-
ity in p-values; thus, subsequent analyses focus on
weight change.
Accounting for multiple comparisons (i.e., four medi-
cation groups), we performed a Bonferroni correction to
identify which groups had significantly different weight
changes from one another (Table 7). The test indicated
that offenders in the antidepressants group had signifi-
cantly different weight changes compared to patients
prescribed other medications. Although the antidepres-
sants – other medications comparison was the only one
Table 5 Antidepressant and Antipsychotic Medications Prescribed to Offenders during 2005–2010
Medication class Generic name Number % of all psychotropics % of sample
Antidepressant Amitriptyline 95 19.2 3.6
BuPROPion 34 6.9 1.3
Citalopram 53 10.7 2
Duloxetine 1 0.2 0
Fluoxetine 45 9.1 1.7
Mirtazapine 52 10.5 2
Paroxetine 19 3.8 0.7
Sertraline 13 2.6 0.5
Venlafaxine 12 2.4 0.5
Total 324 65.3 12.4
Antipsychotic
FGA ChlorproMAZINE 25 5.0 1
Fluphenazine 5 1.0 0.2
Haloperidol 20 4.0 0.8
Loxapine 2 0.4 0.1
Perphenazine 42 8.5 1.6
Thiothixene 5 1.0 0.2
Total 99 20.0 3.8
SGA Aripiprazole 4 0.8 0.2
Olanzapine 3 0.6 0.1
Quetiapine 8 1.6 0.3
Risperidone 55 11.1 2.1
Ziprasidone 3 0.6 0.1
Total 73 14.7 2.8
Table 6 Changes in Weight and BMI for Patients Using Antidepressants and Antipsychotics
Weight change (kg) Percent weight change Change in BMI
95 % CI§ 95 % CI 95 % CI
Medication group Number Mean (SD) [Lower, Upper] Mean (SD) [Lower, Upper] Mean [Lower, Upper]
Antidepressants 324 2.7 (10.1) [1.6, 3.8] 3.8 (11.8) [2.6, 5.1] 0.9 (3.4) [0.6, 1.3]
Antipsychotics 172 2.3 (12.6) [0.4, 4.2] 4.2 (16.1) [1.8, 6.7] 0.8 (4.3) [0.1, 1.4]
Other medications 823 0.8 (9.6) [0.1, 1.5] 1.6 (10.2) [0.9, 2.3] 0.3 (3.1) [0.1, 0.5]
No pharmacotherapy 1409 1.4 (8.1) [1, 1.8] 2.1 (9.5) [1.6, 2.6] 0.4 (2.5) [0.3, 0.6]
Antipsychotics
FGA 99 1.6 (12.8) [−0.9, 4.2] 3.6 (16) [0.4, 6.8] 0.6 (4.3) [−0.3, 1.4]
SGA 73 3.1 (12.3) [0.3, 6] 5.1 (16.2) [1.4, 8.9] 1 (4.2) [0.1, 2]
§ 95 % Confidence Interval
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that satisfied the adjusted significance level, Fig. 1 shows
that antidepressants compared to no pharmacotherapy
was near the cut-off point for significance.
When the antipsychotic subgroup was examined, of-
fenders prescribed SGA gained 1.5 kg more weight com-
pared to the FGA group (Table 6), however this finding
was not significant (p = .448).
African Americans, who were prescribed antidepres-
sants, on average, gained the same weight (2.6 kg) as
Whites taking the same class of medication, which was
not significant (p = .534). In regard to antipsychotics, Af-
rican Americans compared to Whites gained more
weight (3.0 to 2.0 kg, respectively), but this differences
was not significant (p = .157). There were no significant
weight change differences between African Americans
and Whites when the antipsychotic subgroup was
examined. African Americans in the FGA group gained
2.1 kg compared to 1.3 kg for Whites (p = .313). In regard
to SGA, African Americans also gained more weight than
Whites (4.0 and 2.8 kg, respectively), p = .355. While there
were a few significant differences between African
Americans and Whites in regard to length of time
between baseline and last observed weight (i.e., anti-
depressant, p = .035, and FGA, p = .034), the difference for
the antidepressant and FGA groups were 4 and 6 months,
respectively. There were no race differences for length of
time between baseline and last observed weight for other
medication groups.
The Wilcoxon two-sample test indicated that gender
was significant (See Table 8). Women offenders who
were prescribed antidepressants had greater increases in
weight, percent weight change and BMI compared to
men, as shown in Table 8. However, there were no sig-
nificant differences for weight change in regard to gen-
der and antipsychotics. Although women compared to
men gained much more weight, there were no signifi-
cant differences between FGA and SGA use (Table 8). In
regard to length of time between baseline and last re-
corded weight, there were few significant differences
between women and men (Table 8). Although there were
significant gender differences in regard to duration be-
tween baseline and last observed weight for the anti-
psychotic group (p = .027), the difference was 6 months
(Table 8).
Within the population of women offenders, there were
no significant differences among women who were tak-
ing antidepressants (6.4 kg), antipsychotics (8.8 kg),
other medications (4.3 kg) or no pharmacotherapy
(3.7 kg) in regard to changes in weight (p = .423), even
though women prescribed antipsychotics gained the
most weight across groups. Further, women on FGA
gained more weight than women taking SGA (10.8 and
7.3 kg, respectively); however, this differences was not
significant (p = 1.0). There were no significant differ-
ences for weight change (p = .122) within men who were
prescribed antidepressants (2.0 kg), antipsychotics
(1.6 kg), other medications (0.6 kg) or no pharmacother-
apy (1.3 kg). FGA and SGA differences for changes in
Table 7 Bonferroni Adjustment for Multiple Comparisons
Least square means
Comparisons Differences in means 95 % confidence limits [lower, upper]
Antidepressants - Antipsychotics 80.1 [−115.7, 275.9]
Antidepressants - Other medicationsa 154.5 [18.4, 290.6]
Antidepressants - No medication 106.2 [−21.6, 234.1]
Antipsychotics - Other medications 74.4 [−99.6, 248.4]
Antipsychotics - No medication 26.1 [−141.5, 193.7]
Other medications - No medication −48.3 [−139.3, 42.8]
aSignificant
Fig. 1 Bonferroni Adjustment – Significant and Not Significant
Comparisons
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weight for men also were not significant (p = .444), even
though men gained more weight on SGA than men on
FGA (2.5 and 0.9 kg, respectively).
Discussion
This study found that women and men offenders who
were prescribed antidepressants or antipsychotics (FGA
and SGA) gained weight during their incarceration over
similar lengths of time, but the antidepressant group had
weight gain that was significantly different from patients
taking other medications. Weight gain differences be-
tween the antidepressant and no pharmacotherapy groups
approached the significance level. Further, there was no
significant difference in weight gain between SGA and
FGA, even though SGA resulted in greater weight gain
than FGA. There were gender differences in regard to
antidepressant use where women gained significantly
more weight compared to men; however, gender was not
significant for antipsychotics (FGA and SGA). Differences
in weight changes between African Americans and Whites
were not significant for any of the psychotropic agents.
Our results are consistent with previous studies,
primarily outside of corrections, which found an
association between weight gain and antidepressants
(Berkowitz & Fabricatore 2011; Grundy et al. 2014)
and antipsychotics (Bak et al. 2014; Jafari et al. 2012;
Mahmood et al. 2013; Panariello et al. 2012; Tek
et al. 2015; Tiwari et al. 2015; Wang et al. 2013).
Studies have found that the relationship between
mental health, particularly depression, and weight
gain and obesity is greater for women than men
(Berkowitz & Fabricatore 2011; Grundy et al. 2014), which
is similar to the findings of this study where women
gain significantly more weight than men. Race has
been found to be an explanatory factor for differences
in AIWG, in which African Americans who take these
agents have greater rates or odds of gaining weight
compared to Whites and other groups (Chan et al.
2013; Krakowski et al. 2009; Stauffer et al. 2010).
However, this study did not find a significant differ-
ence in weight gain between African American and
White offenders. Further, weight gain experienced by
women on SGA was less than FGA, which is not
consistent with studies attributing greater weight gain
with SGA; however, men had greater weight gain with
SGA, which was expected (Lencz & Malhotra 2009;
Maayan & Correll 2010; Shams & Muller 2014; Zuo
et al. 2015).
Table 8 Antidepressants, Antipsychotics and Gender Differences
Women Men
95 % confidence interval 95 % confidence interval
Mean (SD) [Lower, Upper] Mean (SD) [Lower, Upper] p
Antidepressant n = 53 n = 271
Weight change (kg) 6.4 (11.2) [3.5, 10.0] 2.0 (9.7) [0.8, 3.3] 0.007
Percent weight change 8.5 (15.7) [4.5, 13.6] 2.9 (10.6) [1.7, 4.4] 0.012
BMI change 2.5 (4.4) [1.3, 3.9] 0.6 (3.0) [0.3, 1.1] 0.004
Duration (years)† 2.1 (0.9) [1.8, 2.3] 2.4 (1.1) [2.2, 2.5] 0.055
Antipsychotic n = 16 n = 156
Weight change (kg) 8.8 (17.8) [−0.6, 18.3] 1.6 (11.8) [−0.3, 3.7] 0.122
Percent weight change 13.9 (29.6) [−1.9, 29.6] 3.3 (13.8) [1.2, 5.8] 0.166
BMI change 3.4 (7.2) [−0.4, 7.3] 0.5 (3.8) [−0.1, 1.1] 0.126
Duration (years) 1.9 (1.0) [1.3, 2.4] 2.5 (1.0) [2.3, 2.7] 0.027
FGA n = 7 n = 92
Weight change (kg) 10.8 (17.2) [−5.1, 26.6] 0.9 (12.2) [−1.7, 3.7] 0.096
Percent weight change 15.8 (31.4) [−13.3, 44.8] 2.7 (14.1) [−0.3, 6.0] 0.142
BMI change 4.1 (7.2) [−2.5, 10.8] 0.3 (3.9) [−0.5, 1.2] 0.094
Duration (years) 1.7 (1.0) [0.7, 2.6] 2.4 (1.1) [2.2, 2.6] 0.093
SGA n = 9 n = 64
Weight change (kg) 7.3 (19.2) [−7.4, 22.1] 2.5 (11.1) [−0.2, 5.6] 0.568
Percent weight change 12.4 (29.8) [−10.5, 35.3] 4.1 (13.3) [0.8, 7.8] 0.633
BMI change 2.9 (7.6) [−3.0, 8.8] 0.8 (3.5) [−0.1, 1.7] 0.609
Duration (years) 2 (1.1) [1.2, 2.8] 2.7 (1.0) [2.4, 2.9] 0.100
† Length of time between baseline and last observed weight
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The finding that antipsychotics, particularly SGA, were
not associated with significant or greater weight in com-
parison to FGA may be related to the absence of cloza-
pine and very few offenders prescribed olanzapine,
which have been found to contribute to weight gain
more so than other SGA (Arterburn et al. 2015; Ameri-
can Diabetes Association et al. 2004; Jafari et al. 2012;
Krakowski et al. 2009; Shams & Muller 2014; Tek et al.
2015; Wang et al. 2013). FGA for this DOC also were
prescribed more often than SGA. Further, it has been
found that women prescribed risperidone, of which a
plurality of women offenders in this DOC used, experi-
enced greater weight gain in comparison to men (Hung
et al. 2010), which may explain, in part, the SGA gender
disparity. Thus, the SGA gender findings may be ex-
plained by the heterogeneity of these drugs in regard to
weight gain (Softic et al. 2015; ÜÇOk & Gaebel 2008),
but the greater weight gain among women who used
FGA compared to SGA requires further investigation.
Antidepressant (Barnard et al. 2013; Kivimäki et al.
2011; Pan et al. 2012; Wu et al. 2014; Yoon et al. 2013)
and antipsychotic (Chaggar et al. 2011; American Dia-
betes Association et al. 2004; Fernandez-Egea et al. 2011;
Goff et al. 2005; Green et al. 2015; Ward et al. 2013;
Wysokinski et al. 2012) studies have found these agents
a risk factor for metabolic syndrome or dysregulation.
The risk of type 2 diabetes was associated with anti-
depressant and antipsychotic use, as these agents dis-
rupted glucose metabolism (Barnard et al. 2013;
Fernandez-Egea et al. 2011; Green et al. 2015; Mahmood
et al. 2013; Wang et al. 2013; Wysokinski et al. 2012).
Studies also found that some antipsychotic agents (e.g.,
olanzapine) were associated with increases in low-
density lipoprotein, triglycerides and total cholesterol
(Fernandez-Egea et al. 2011; Wysokinski et al. 2012). In-
creased risk of type 2 diabetes and dyslipidemia related
to antidepressant and antipsychotic use may have a
moderating effect on weight gain, particularly for SGA,
since offenders who developed these diseases are more
likely to have encounters with primary care physicians,
increasing the likelihood of weight management.
The EHR for this DOC was used by psychiatrists, pri-
mary care physicians and mental health professionals en-
gaged in the care of offenders diagnosed with depression
or psychotic symptoms. The EHR provided psychiatrists
and primary care physicians full access to the medication
history, diagnosis list, vital statistics and lab data for pa-
tients they shared. Thus, mental and physical health
were not provided in isolation from one another or
dependent upon patients to communicate their health
history to the two specialties. While the EHR may not
have embodied multidisciplinary healthcare teams, it de-
creased barriers in regard to specialties accessing pa-
tients’ complete health history. Further, offenders with
depression or psychoses, who also had chronic diseases,
were seen minimally 3–4 times per year, depending
upon national standards and disease control. Chronic
disease clinics provided an opportunity for primary care
physicians to intervene or counsel offenders who gain
weight.
Conclusion
Providing mental health treatment in a correctional en-
vironment is complex, especially given the focus on
safety and security of offenders, correctional staff and
the public. However, there are structural advantages for
providing healthcare in a closed environment, such as
corrections, which has extensive knowledge about its pa-
tient population and is able to assign patients to chronic
disease clinics. Findings from the literature also posit
that mental health and incarceration is complex whereby
some offenders perceive the prison environment as a
contributor to their poor mental health status whereas
others see corrections as an opportunity for healthcare
services (Goomany & Dickinson 2015; Walker et al.
2014). While beyond the scope of this study, offenders
in this DOC received mental health pharmacotherapy in
similar proportions to national data (Glaze & James
2006), but it is unknown why there was greater use of
FGA compared to SGA.
SGA have been found to have fewer extrapyramidal side
effects, such as Parkinsonian and akathisia, and a lower
risk of tardive dyskinesia compared to FGA (Gallego et al.
2012; Lencz & Malhotra 2009; ÜÇOk & Gaebel 2008), but
typically are more expensive (Gallego et al. 2012). Con-
versely, metabolic syndrome and weight gain side effects
have been associated most strongly with SGA (Gallego
et al. 2012). Further, it has been posited that FGA side ef-
fects (e.g., extrapyramidal) are attenuated by low dose, and
the comparative effectiveness of SGA in regard to FGA is
debated (Gallego et al. 2012). Thus, corrections may be
managing its population effectively while also containing
cost. Correctional systems understand the importance of
providing care to offenders who have mental health diag-
noses, even if the perspective is based on security con-
cerns, that is, corrections does not have the luxury of
having untreated offenders with depression or psychotic
symptoms; this would be counter to maintaining secur-
ity. However, gender disparities, particularly to the
detriment of women, is a recurrent finding in correc-
tional health studies, especially as it relates to weight
gain or obesity (Clarke & Waring 2012; Gates &
Bradford 2015; Herbert et al. 2012).
The emerging findings of this study suggest promise, but
also an opportunity to intervene particularly in the health
of women offenders who are prescribed antidepressant
and/or antipsychotic agents. Based on the preliminary find-
ings of this study, there are several recommendations that
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we propose for the short and long-term. The intake process
typically includes multiple health screenings and assess-
ment tools. We propose that departments of corrections re-
view its screening tools and procedures related to the use
of psychotropic agents to determine if there are weight
management interventions, particularly for the population
most at risk. Further investigations of antidepressant and
antipsychotic related weight gain likely will result in screen-
ing tools becoming risk assessment or predictive instru-
ments, which we would recommend corrections adopt.
Corrections, in collaboration with academic partners, likely
will improve the mental and physical health of its popula-
tion by learning more about the psychosocial factors of the
population prescribed psychotropic agents, which may ad-
dress underlying mental health issues, including the effects
of incarceration.
Limitations
This study is among the few studies to have investigated
psychotropic agents (i.e., antidepressants and antipsy-
chotics) and weight gain in corrections. There were several
limitations for this study, principally, the lack of medication
history for offenders during their incarceration. Studies in-
vestigating antidepressant and antipsychotic use have found
dose (ÜÇOk & Gaebel 2008) and duration (Bak et al. 2014;
Tek et al. 2015) factors related to weight gain. A more ex-
tensive and complete medication and mental health history
would have identified which offenders were antidepressant
and antipsychotic naïve patients and what effect medication
switching, polypharmacy or mental health severity may
have had. In addition to antidepressant and antipsychotic
medication history, this study did not collect adherence
data to evaluate whether or not adherence correlated with
weight gain or explained findings inconsistent with the lit-
erature, such as greater weight gain from FGA compared to
SGA. Other studies have found antidepressant and anti-
psychotic medications are a contributor to metabolic syn-
drome, but this study did not investigate the weight gain
effect that these drugs may have had in regard to risk for
related chronic diseases. The inclusion and exclusion cri-
teria resulted in a large percent of missing data for women
offenders (a 3.7 % under sampling for the group when com-
pared to the total population).
This study focused on descriptively investigating the ef-
fect of antidepressant and antipsychotic induced weight
gain with a focus on race and gender differences. The find-
ings of this study suggest further investigation is needed to
understand the effect of mental health severity, medication
history, metabolic syndrome and to explain gender dispar-
ities. Multivariable analyses will be needed to adjust for the
effects from confounding factors with appropriate collinear-
ity procedure (Yoo et al. 2014). Furthermore, data-mining
methods like tree-based approaches or random forests may
effectively capture moderation effects associated with
antidepressant and antipsychotic use and weight gain (Yoo
et al. 2012).
Abbreviations
AIWG: antipsychotic induced weight gain; BMI: body mass index;
DOC: Department of Corrections; EHR: electronic health record; FGA: first
generation antipsychotic; ICD: international statistical classification of
diseases; NDC: National Drug Code; OMS: offender management system;
SGA: second generation antipsychotic; SNOMED: systematized nomenclature
of medicine; WHO: World Health Organization.
Acknowledgements
We thank the Institute of Preventive and Public Health at Augusta University
for providing support, time and resources to conduct the study.
Authors’ contributions
MG and VW developed the initial concept for the study. MG and VW drafted
the background. WY and MG drafted the methods and results. TW and EF
drafted and explained clinical findings. MG, TW and EF drafted the
discussion. All authors drafted the conclusion. All authors edited and
approved the final manuscript.
Competing interests




This retrospective study was approved by the IRB (Protocol number: 10-0382F2L)
at the University of Kentucky. The IRB approved a waiver of consent.
Author details
1Department of Family Medicine, Medical College of Georgia, Institute of
Public and Preventive Health, Augusta University, 1120 15th Street,
CJ – 2300, Augusta, GA 30912, USA. 2Department of Family Medicine,
Medical College of Georgia, Augusta University, 1120 15th Street, HB – 4000,
Augusta, GA 30912, USA. 3Department of Psychiatry and Health Behavior,
Medical College of Georgia, Augusta University, 997 St. Sebastian Way,
Augusta, GA 30912, USA. 4Lexington Public Library, 3628 Walden Drive,
Lexington, KY 40517, USA. 5Centurion, LLC, 53 Century Blvd, Suite 150,
Nashville, TN 37214, USA. 6Dental College of Georgia, Institute of Public and
Preventive Health, Augusta University, 1120 15th Street, CJ – 2300, Augusta,
GA 30912, USA.
Received: 2 March 2016 Accepted: 17 May 2016
References
American Diabetes Association; American Psychiatric Association; American
Association of Clinical Endocrinologists; North American Association for the
Study of Obesity. (2004). Consensus development conference on
antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596–601.
Arterburn, D, Wood, GC, Theis, MK, Westbrook, EO, Anau, J, Rukstalis, M,
Boscarino, JA, Daar, Z, & Gerhard, GS. (2015). Antipsychotic medications and
extreme weight gain in two health systems. Obesity Research & Clinical
Practice. doi: 10.1016/j.orcp.2015.08.012
Bai, JR, Befus, M, Mukherjee, DV, Lowy, FD, & Larson, EL (2015). Prevalence
and Predictors of Chronic Health Conditions of Inmates Newly Admitted
to Maximum Security Prisons. Journal of Correctional Health Care: the
Official Journal of the National Commission on Correctional Health Care,
21(3), 255–264. doi:10.1177/1078345815587510.
Bak, M, Fransen, A, Janssen, J, van Os, J, & Drukker, M (2014). Almost all
antipsychotics result in weight gain: a meta-analysis. PloS One, 9(4), e94112.
doi:10.1371/journal.pone.0094112.
Barnard, K, Peveler, RC, & Holt, RIG (2013). Antidepressant Medication as a Risk
Factor for Type 2 Diabetes and Impaired Glucose Regulation: Systematic
review. Diabetes Care, 36(10), 3337–3345. doi:10.2337/dc13-0560.
Berkowitz, RI, & Fabricatore, AN (2011). Obesity, psychiatric status, and psychiatric
medications. Psychiatric Clinics of North America, 34(4), 747–764. doi:10.1016/j.
psc.2011.08.007.
Gates et al. Health and Justice  (2016) 4:6 Page 10 of 12
Bet, PM, Hugtenburg, JG, Penninx, BWJH, & Hoogendijk, WJG (2013). Side effects
of antidepressants during long-term use in a naturalistic setting. European
Neuropsychopharmacology, 23(11), 1443–1451. doi: http://dx.doi.org/10.1016/j.
euroneuro.2013.05.001.
CDC (2015). Adult Obesity Causes & Consequences. National Center for Chronic
Disease Prevention and Promotion. http://www.cdc.gov/obesity/adult/causes.
html. Accessed 29 Oct 2015.
Chaggar, PS, Shaw, SM, & Williams, SG (2011). Effect of Antipsychotic Medications on
Glucose and Lipid Levels. The Journal of Clinical Pharmacology, 51(5), 631–638.
doi:10.1177/0091270010368678.
Chan, LF, Zai, C, Monda, M, Potkin, S, Kennedy, JL, Remington, G, Lieberman, J,
Meltzer, HY, & De Luca, V (2013). Role of ethnicity in antipsychotic-induced
weight gain and tardive dyskinesia: genes or environment?
Pharmacogenomics, 14(11), 1273–1281. doi:10.2217/pgs.13.127.
Clarke, JG, & Waring, ME (2012). Overweight, obesity, and weight change
among incarcerated women. Journal of Correctional Health Care: the
Official Journal of the National Commission on Correctional Health Care,
18(4), 285–292. doi:10.1177/1078345812456010.
Curtis, J, Watkins, A, Rosenbaum, S, Teasdale, S, Kalucy, M, Samaras, K, & Ward, PB.
(2015). Evaluating an individualized lifestyle and life skills intervention to
prevent antipsychotic-induced weight gain in first-episode psychosis. Early
intervention in psychiatry. doi:10.1111/eip.12230
Fava, M, Wisniewski, SR, Thase, ME, Baker, RA, Tran, QV, Pikalov, A, Yang, H,
Marcus, RN, & Berman, RM (2009). Metabolic assessment of aripiprazole as
adjunctive therapy in major depressive disorder: a pooled analysis of 2
studies. Journal of Clinical Psychopharmacology, 29(4), 362–367. doi:10.1097/
JCP.0b013e3181ac9b0b.
Fernandez-Egea, E, Miller, B, Garcia-Rizo, C, Bernardo, M, & Kirkpatrick, B (2011).
Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis.
Journal of Clinical Psychopharmacology, 31(2), 154–159. doi:10.1097/JCP.
0b013e31820fcea3.
Fonseka, TM, Tiwari, AK, Goncalves, VF, Lieberman, JA, Meltzer, HY, Goldstein, BI,
Kennedy, JL, Kennedy, SH, & Muller, DJ (2015). The role of genetic variation
across IL-1beta, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain.
The World Journal of Biological Psychiatry: the Official Journal of the World
Federation of Societies of Biological Psychiatry, 16(1), 45–56. doi:10.3109/
15622975.2014.984631.
Gallego, JA, Nielsen, J, De Hert, M, Kane, JM, & Correll, CU (2012). Safety and
Tolerability of Antipsychotic Polypharmacy. Expert Opinion on Drug Safety,
11(4), 527–542. doi:10.1517/14740338.2012.683523.
Gates, ML, & Bradford, RK (2015). The impact of incarceration on obesity: are
prisoners with chronic diseases becoming overweight and obese during
their confinement? Journal of Obesity, 2015, 532468. doi:10.1155/2015/532468.
Ghanizadeh, A, Nikseresht, MS, & Sahraian, A (2013). The effect of zonisamide on
antipsychotic-associated weight gain in patients with schizophrenia: A
randomized, double-blind, placebo-controlled clinical trial. Schizophrenia
Research, 147(1), 110–115. doi:10.1016/j.schres.2013.03.021.
Glaze L, & James, D (2006). Mental Health Problems of Prison and Jail Inmates.
Bureau of Justice Statistics. Retrieved from http://www.bjs.gov/index.
cfm?ty=pbdetail&iid=789. Accessed 15 Aug 2013.
Goff, DC, Sullivan, LM, McEvoy, JP, Meyer, JM, Nasrallah, HA, Daumit, GL, Lamberti,
S, D'Agostino, RB, Stroup, TS, Davis, S, & Lieberman, JA (2005). A comparison
of ten-year cardiac risk estimates in schizophrenia patients from the CATIE
study and matched controls. Schizophrenia Research, 80(1), 45–53.
doi:10.1016/j.schres.2005.08.010.
Goomany, A, & Dickinson, T (2015). The influence of prison climate on the mental
health of adult prisoners: a literature review. Journal of Psychiatric and Mental
Health Nursing, 22(6), 413–422. doi:10.1111/jpm.12231.
Green, CA, Yarborough, BJH, Leo, MC, Yarborough, MT, Stumbo, SP, Janoff, SL,
Perrin, NA, Nichols, GA, & Stevens, VJ (2015). The STRIDE Weight Loss and
Lifestyle Intervention for Individuals taking Antipsychotic Medications: A
Randomized Trial. The American Journal of Psychiatry, 172(1), 71–81.
doi:10.1176/appi.ajp.2014.14020173.
Grundy, A, Cotterchio, M, Kirsh, VA, & Kreiger, N (2014). Associations between
anxiety, depression, antidepressant medication, obesity and weight gain
among Canadian women. PloS One, 9(6), e99780. doi:10.1371/journal.pone.
0099780.
Hassan, L, Frisher, M, Senior, J, Tully, M, Webb, R, While, D, & Shaw, J (2014).
Health Services and Delivery Research A cross-sectional prevalence survey of
psychotropic medication prescribing patterns in prisons in England.
Southampton: NIHR Journals Library.
Heiskanen, TH, Koivumaa-Honkanen, HT, Niskanen, LK, Lehto, SM, Honkalampi, KM,
Hintikka, JJ, & Viinamaki, HT (2013). Depression and major weight gain: a 6-year
prospective follow-up of outpatients. Comprehensive Psychiatry, 54(6), 599–604.
doi:10.1016/j.comppsych.2013.02.001.
Henderson, DC, Vincenzi, B, Andrea, NV, Ulloa, M, & Copeland, PM (2015).
Pathophysiological mechanisms of increased cardiometabolic risk in people
with schizophrenia and other severe mental illnesses. The Lancet Psychiatry,
2(5), 452–464. doi:10.1016/s2215-0366(15)00115-7.
Herbert, K, Plugge, E, Foster, C, & Doll, H (2012). Prevalence of risk factors for
non-communicable diseases in prison populations worldwide: a
systematic review. Lancet (London, England), 379(9830), 1975–1982.
doi:10.1016/s0140-6736(12)60319-5.
Hung, GCL, Kuo, C-J, Huang, M-C, Kao, L-H, & Chen, Y-Y (2010). Sex differences in
the association of weight gain and risperidone efficacy among schizophrenic
patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry,
34(8), 1523–1524. doi:10.1016/j.pnpbp.2010.08.002.
Jacobowitz, W, Derbabian, B, & Saunders, A (2014). The effect of a calorie-
restricted diet on weight gain in short-term psychiatric inpatients
receiving atypical antipsychotic medications. Journal of Psychosocial
Nursing and Mental Health Services, 52(7), 30–37. doi:10.3928/02793695-
20140421-01.
Jafari, S, Fernandez-Enright, F, & Huang, XF (2012). Structural contributions of
antipsychotic drugs to their therapeutic profiles and metabolic side
effects. Journal of Neurochemistry, 120(3), 371–384. doi:10.1111/j.1471-
4159.2011.07590.x.
Keers, R, & Aitchison, KJ (2010). Gender differences in antidepressant drug
response. International Review of Psychiatry, 22(5), 485–500. doi:10.3109/
09540261.2010.496448.
Kivimäki, M, Batty, GD, Jokela, M, Ebmeier, KP, Vahtera, J, Virtanen, M, Brunner, EJ,
Tabak, AG, Witte, DR, Kumari, M, Singh-Manoux, A, & Hamer, M et al. (2011).
Antidepressant Medication Use and Risk of Hyperglycemia and Diabetes
Mellitus—A Noncausal Association? Biological Psychiatry, 70(10), 978–984.
doi:10.1016/j.biopsych.2011.07.008.
Krakowski, M, Czobor, P, & Citrome, L. (2009). Weight gain, metabolic parameters,
and the impact of race in aggressive inpatients randomized to double-blind
clozapine, olanzapine or haloperidol. Schizophrenia Research, 110(1–3),
95–102. doi:10.1016/j.schres.2009.02.006.
Lencz, T, & Malhotra, AK (2009). Pharmacogenetics of antipsychotic-induced side
effects. Dialogues in Clinical Neuroscience, 11(4), 405–415.
Maayan, L, & Correll, CU (2010). Management of Antipsychotic-Related Weight
Gain. Expert Review of Neurotherapeutics, 10(7), 1175–1200. doi:10.1586/
ern.10.85.
Mahmood, S, Booker, I, Huang, J, & Coleman, CI (2013). Effect of topiramate
on weight gain in patients receiving atypical antipsychotic agents.
Journal of Clinical Psychopharmacology, 33(1), 90–94. doi:10.1097/JCP.
0b013e31827cb2b7.
Maruschak, LM, Berzofsky, M, & Unangst, J (2015). Medical Problems of State and
Federal Prisoners and Jail Inmates, 2011–12. Bureau of Justice Statistics.
http://www.bjs.gov/index.cfm?ty=pbdetail&iid=5219. Accessed 4 Dec 2015.
Mizuno, Y, Suzuki, T, Nakagawa, A, Yoshida, K, Mimura, M, Fleischhacker, WW, &
Uchida, H (2014). Pharmacological strategies to counteract antipsychotic-
induced weight gain and metabolic adverse effects in schizophrenia: a
systematic review and meta-analysis. Schizophrenia Bulletin, 40(6), 1385–1403.
doi:10.1093/schbul/sbu030.
Noordam, R, Aarts, N, Tiemeier, H, Hofman, A, Stricker, BH, & Visser, LE (2015).
Sex-specific association between antidepressant use and body weight in a
population-based study in older adults. The Journal of Clinical Psychiatry,
76(6), e745–e751. doi:10.4088/JCP.13m08896.
Pan, A, Sun, Q, Okereke, OI, Rexrode, KM, Rubin, RR, Lucas, M, Willett, WC,
Manson, JE, & Hu, FB (2012). Use of antidepressant medication and risk of
type 2 diabetes: results from three cohorts of US adults. Diabetologia, 55(1),
63–72. doi:10.1007/s00125-011-2268-4.
Panariello, F, Polsinelli, G, Borlido, C, Monda, M, & De Luca, V (2012). The role of
leptin in antipsychotic-induced weight gain: genetic and non-genetic factors.
Journal of Obesity, 2012, 572848. doi:10.1155/2012/572848.
Papanastasiou, E (2013). The prevalence and mechanisms of metabolic syndrome
in schizophrenia: a review. Therapeutic Advances in Psychopharmacology, 3(1),
33–51. doi:10.1177/2045125312464385.
Seeman, MV (2010). Schizophrenia: women bear a disproportionate toll of
antipsychotic side effects. Journal of the American Psychiatric Nurses
Association, 16(1), 21–29. doi:10.1177/1078390309350918.
Gates et al. Health and Justice  (2016) 4:6 Page 11 of 12
Shams, TA, & Muller, DJ (2014). Antipsychotic induced weight gain: genetics,
epigenetics, and biomarkers reviewed. Current Psychiatry Reports, 16(10), 473.
doi:10.1007/s11920-014-0473-9.
Softic, R, Sutovic, A, Avdibegovic, E, Osmanovic, E, Becirovic, E, & Hajdukov, MM
(2015). Metabolic syndrome in schizophrenia - who is more to blame: FGA
polypharmacy or clozapine monotherapy? Psychiatria Danubina, 27(4), 378–384.
Stauffer, VL, Sniadecki, JL, Piezer, KW, Gatz, J, Kollack-Walker, S, Hoffmann, VP,
Conley, R, & Durell, T (2010). Impact of race on efficacy and safety during
treatment with olanzapine in schizophrenia, schizophreniform or
schizoaffective disorder. BMC Psychiatry, 10, 89. doi:10.1186/1471-244x-10-89.
Tek, C, Guloksuz, S, Srihari, VH, & Reutenauer, EL (2013). Investigating the safety
and efficacy of naltrexone for anti-psychotic induced weight gain in severe
mental illness: study protocol of a double-blind, randomized, placebo-
controlled trial. BMC Psychiatry, 13, 176. doi:10.1186/1471-244x-13-176.
Tek, C, Kucukgoncu, S, Guloksuz, S, Woods, SW, Srihari, VH, & Annamalai, A (2015).
Antipsychotic-induced weight gain in first-episode psychosis patients: a
meta-analysis of differential effects of antipsychotic medications. Early
intervention in psychiatry. doi:10.1111/eip.12251
Tiwari, AK, Brandl, EJ, Zai, CC, Goncalves, VF, Chowdhury, NI, Freeman, N, Lieberman,
JA, Meltzer, HY, Kennedy, JL, & Muller, DJ. (2015). Association of orexin receptor
polymorphisms with antipsychotic-induced weight gain. The world journal of
biological psychiatry: the official journal of the World Federation of Societies of
Biological Psychiatry, 1–9. doi:10.3109/15622975.2015.1076173
ÜÇOk, ALP, & Gaebel, W (2008). Side effects of atypical antipsychotics: a brief
overview. World Psychiatry, 7(1), 58–62.
Visher, CA, & Bakken, NW (2014). Reentry challenges facing women with mental health
problems. Women & Health, 54(8), 768–780. doi:10.1080/03630242.2014.932889.
Walker, J, Illingworth, C, Canning, A, Garner, E, Woolley, J, Taylor, P, & Amos, T
(2014). Changes in mental state associated with prison environments: a
systematic review. Acta Psychiatrica Scandinavica, 129(6), 427–436.
doi:10.1111/acps.12221.
Wang, Ree, S-C, Huang, Y-S, Hsiao, C-C, & Chen, C-K (2013). Adjunctive effects of
aripiprazole on metabolic profiles: Comparison of patients treated with
olanzapine to patients treated with other atypical antipsychotic drugs.
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 40, 260–266.
doi: http://dx.doi.org/10.1016/j.pnpbp.2012.10.010.
Wang, PS, Wu, SL, & Ching, HY (2014). The use of psychiatric drugs and
worsening body mass index among inpatients with schizophrenia.
International Clinical Psychopharmacology, 29(4), 235–238. doi:10.1097/yic.
0000000000000027.
Ward, A, Quon, P, Abouzaid, S, Haber, N, Ahmed, S, & Kim, E (2013).
Cardiometabolic consequences of therapy for chronic schizophrenia using
second-generation antipsychotic agents in a medicaid population: clinical
and economic evaluation. P & T : a Peer-reviewed Journal for Formulary
Management, 38(2), 109–115.
WHO (2004). Appropriate body-mass index for Asian populations and its
implications for policy and intervention strategies. The Lancet, 363(9403),
157–163. doi: 10.1016/S0140-6736(03)15268-3.
Wolff, N, Shi, J, Fabrikant, N, & Schumann, BE (2012). Obesity and weight-
related medical problems of incarcerated persons with and without
mental disorders. Journal of Correctional Health Care: the Official
Journal of the National Commission on Correctional Health Care, 18(3),
219–232. doi:10.1177/1078345812445270.
Wu, RR, Jin, H, Gao, K, Twamley, EW, Ou, JJ, Shao, P, Wang, J, Guo, XF, Davis, JM,
Chan, PK, & Zhao, JP (2012). Metformin for treatment of antipsychotic-induced
amenorrhea and weight gain in women with first-episode schizophrenia: a
double-blind, randomized, placebo-controlled study. The American Journal of
Psychiatry, 169(8), 813–821. doi:10.1176/appi.ajp.2012.11091432.
Wu, CS, Gau, SS, & Lai, MS (2014). Long-term antidepressant use and the risk of
type 2 diabetes mellitus: a population-based, nested case–control study in
Taiwan. The Journal of Clinical Psychiatry, 75(1), 31–38. doi:10.4088/JCP.
13m08421. quiz 38.
Wysokinski, A, Kowman, M, & Kloszewska, I (2012). The prevalence of metabolic
syndrome and Framingham cardiovascular risk scores in adult inpatients
taking antipsychotics - a retrospective medical records review. Psychiatria
Danubina, 24(3), 314–322.
Yoo, W, Ference, BA, Cote, ML, & Schwartz, A (2012). A Comparison of Logistic
Regression, Logic Regression, Classification Tree, and Random Forests to
Identify Effective Gene-Gene and Gene-Environmental Interactions.
International Journal of Pure and Applied Sciences and Technology, 2(7), 268.
Yoo, W, Mayberry, R, Bae, S, Singh, K, Peter He, Q, & Lillard, JW (2014). A Study of
Effects of MultiCollinearity in the Multivariable Analysis. International Journal
of Pure and Applied Sciences and Technology, 4(5), 9–19.
Yoon, JM, Cho, E-G, Lee, H-K, & Park, SM (2013). Antidepressant Use and Diabetes
Mellitus Risk: A Meta-Analysis. Korean Journal of Family Medicine, 34(4), 228–240.
doi:10.4082/kjfm.2013.34.4.228.
Zheng, W, Li, XB, Tang, YL, Xiang, YQ, Wang, CY, & de Leon, J (2015). Metformin for
Weight Gain and Metabolic Abnormalities Associated With Antipsychotic
Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. Journal of
Clinical Psychopharmacology, 35(5), 499–509. doi:10.1097/jcp.0000000000000392.
Zuo, S, Fries, BE, Szafara, K, & Regal, R (2015). Valproic Acid as a potentiator of
metabolic syndrome in institutionalized residents on concomitant
antipsychotics: fat chance, or slim to none? P & T: a Peer-reviewed Journal for
Formulary Management, 40(2), 126–132.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Gates et al. Health and Justice  (2016) 4:6 Page 12 of 12
